NuPulse is a medical device company that develops technology to treat patients with heart failure. The device, which requires minimally invasive surgery, provides patients an alternative to medical therapy. NuPulse has a strategic and financial partnership with one of the heart failure companies in the world. NuPulse’s founders have extensive clinical, engineering, and life science experience, which will allow them, along with their strategic partner and Broadview Ventures, to alter the paradigm for the treatment of heart failure. The iVAS medical device (ambulatory counterpulsation) by NuPulseCV is being evaluated through a clinical trial as an option for patients who have advanced heart failure and who are no longer benefiting from guideline-directed medical therapies. The iVAS is a less invasive option that may help address heart failure symptoms (NYHA III and IV), which may allow a heart failure patient to return to daily activities. NuPulse was formed in 2010 and is headquartered in Raleigh, North Carolina, United States.